Travere Therapeutics, Inc. (TVTX) News

Travere Therapeutics, Inc. (TVTX): $28.24

-0.35 (-1.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TVTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter TVTX News Items

TVTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TVTX News Highlights

  • TVTX's 30 day story count now stands at 7.
  • Over the past 28 days, the trend for TVTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about TVTX are CM, BP and CCO.

Latest TVTX News From Around the Web

Below are the latest news stories about Travere Therapeutics Inc that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2021 Results - Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Chris Cline - SVP, IR & Corporate Communications Eric Dube - CEO Jula Inrig - CMO Peter Heerma - CCO Laura Clague - CFO Bill Rote - SVP of Research & Development Conference...

SA Transcripts on Seeking Alpha | February 25, 2022

Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA nephropathy and FSGS MAA submission mid-year 2022 Recently reported positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria Net product sales increased six percent to $211 million for the full year 2021 SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Trave

Yahoo | February 24, 2022

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 70,600 shares of its common stock to seven new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 45,600 shares of its common sto

Yahoo | February 14, 2022

Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date: Thursday, February 24, 2022Time: 4:30 p.m. ETDial-in numbers: +1 (855) 219-921

Yahoo | February 10, 2022

Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. ET. A live webcast will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We

Yahoo | February 9, 2022

CM Management, LLC Buys Cadence Bank, Cadence Bank, Agnico Eagle Mines, Sells Cadence Bank, ...

Investment company CM Management, LLC (Current Portfolio) buys Cadence Bank, Cadence Bank, Agnico Eagle Mines, Chesapeake Energy Corp, mCloud Technologies Corp, sells Cadence Bank, Cadence Bank, Travere Therapeutics Inc, BP PLC, EnLink Midstream LLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CM Management, LLC.

Yahoo | February 2, 2022

Americana Partners, LLC Buys Adobe Inc, Apple Inc, Meta Platforms Inc, Sells Amazon. ...

Investment company Americana Partners, LLC (Current Portfolio) buys Adobe Inc, Apple Inc, Meta Platforms Inc, Microsoft Corp, Procter & Gamble Co, sells Amazon.com Inc, Exxon Mobil Corp, IQ MacKay Municipal Insured ETF, Illumina Inc, Netflix Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Americana Partners, LLC.

Yahoo | January 28, 2022

Health Check: How Prudently Does Travere Therapeutics (NASDAQ:TVTX) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | January 11, 2022

Travere Therapeutics Provides Corporate Update and 2022 Outlook

Company positioned for multiple NDA and MAA submissions for accelerated approval in 2022SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2021 to be approximately $55 million. For the fiscal year 2021, the Company expects total revenue of $227 million, inclusive of approximately $211 million in net product sales and approximately

Yahoo | January 10, 2022

Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmenta

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5691 seconds.